A Nature Medicine guideline sets shared rules for personalized phage therapy and does not recommend it as routine care

What the research found

ScienceDaily dated its page 4 November 2026. The feed clock, 21:40 Eastern on 4 November, is 5 November in Bangkok. The piece covers a Nature Medicine consensus guideline, DOI 10.1038/s41591-026-04654-6, volume 32, page 3578. An international group led through the German Society for Infectious Diseases, with 20 professional organizations, wrote more than 60 recommendations on how bacteriophages for a named patient should be chosen, tested, made, given, and watched. The guideline does not recommend phage therapy as routine care for bacterial infections. It says controlled trials have not yet shown how reliably it works, and that it may be considered when standard treatment has failed, is unavailable, or cannot be used safely. A Belgian case series of 100 people, cited as earlier experience rather than as a result of this guideline, reported clinical improvement in 77 percent and loss of the targeted bacteria in 61 percent. The ScienceDaily account also says Frankfurt University Medical Center has treated 10 patients since February 2026 under the guideline. That center count is not a controlled trial. The recommendations are described as valid from 5 January 2026 through 29 June 2030. Not medical advice.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at ScienceDaily